These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24624702)

  • 21. One step closer to elimination of hepatitis C in Egypt.
    Esmat G; El-Sayed MH; Hassany M; Doss W; Waked I;
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):665. PubMed ID: 30215356
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection].
    Desenclos JC; Dubois F; Mariotte N; Goudeau A
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S25-32. PubMed ID: 9161511
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
    Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
    Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
    Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
    Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
    Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example.
    Altraif I
    Saudi Med J; 2018 Aug; 39(8):842-845. PubMed ID: 30106425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?
    Darke J; Cresswell T; McPherson S; Hamoodi A
    J Public Health (Oxf); 2016 Dec; 38(4):e554-e562. PubMed ID: 28158850
    [No Abstract]   [Full Text] [Related]  

  • 29. Outcomes and costs of care in hepatitis C: combination therapy scores again.
    Koff RS
    Am J Gastroenterol; 2000 Jun; 95(6):1392-3. PubMed ID: 10894568
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis C could be virtually eliminated by 2030, experts believe.
    Watts G
    BMJ; 2014 Apr; 348():g2700. PubMed ID: 24721972
    [No Abstract]   [Full Text] [Related]  

  • 31. [Medical and economic evaluation of donated blood screening for hepatitis C and non-A, non-B, non-C hepatitis].
    Vergnon P; Colin C; Jullien AM; Bory E; Excoffier S; Matillon Y; Trepo C
    Rev Epidemiol Sante Publique; 1996 Jan; 44(1):66-79. PubMed ID: 8851944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of hepatitis C with new direct antiviral drugs: towards a disease cure].
    Halfon P; Cacoub P
    Rev Med Interne; 2014 Apr; 35(4):219-21. PubMed ID: 24559772
    [No Abstract]   [Full Text] [Related]  

  • 33. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.
    Wörmann B
    Dtsch Arztebl Int; 2017 Jan; 114(1-02):9-10. PubMed ID: 28143634
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatitis C: how has France limited the expenses related to new treatments?
    Mouterde AL; Bocquet F; Fusier I; Paubel P
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):655-657. PubMed ID: 27732130
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prescription of new HCV-drugs - what has to be considered judicially].
    Mauss S
    Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eliminating HCV: a marathon, not a sprint.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2020 Jun; 5(6):515. PubMed ID: 32416859
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathways to the elimination of hepatitis C: prioritising access for all.
    Pedrana AE; Sacks-Davis R; Doyle JS; Hellard ME
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1023-1026. PubMed ID: 28942660
    [No Abstract]   [Full Text] [Related]  

  • 38. MEDICINE. Global control of hepatitis C virus.
    Cox AL
    Science; 2015 Aug; 349(6250):790-1. PubMed ID: 26293940
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C in state correctional facilities.
    Spaulding A; Greene C; Davidson K; Schneidermann M; Rich J
    Prev Med; 1999 Jan; 28(1):92-100. PubMed ID: 9973592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C: only a step away from elimination?
    Lancet; 2015 Mar; 385(9973):1045. PubMed ID: 25797543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.